Alembic Pharmaceuticals climbed 3.07% to Rs 930.50 after the company said it has received final USFDA approval for its ANDA for Diltiazem Hydrochloride tablets.
Alembic Pharmaceuticals' shares are expected to draw attention following the USFDA's approval of its key hypertension drug, Diltiazem Hydrochloride Tablets.
The company said this development further strengthens its US generics business and adds depth to its offerings in the cardiovascular segment.
Alembic Pharma received USFDA approval for its generic Dasatinib Tablets (20–140 mg), equivalent to Sprycel by BMS. The drug ...
Capital Market on MSN
Alembic Pharma gets US FDA approval for angina treatment drug Diltiazem
Alembic Pharmaceuticals said that it has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Diltiazem Hydrochloride Tablets USP.
Alembic Pharma receives US FDA final approval for diltiazem HCl tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg: Our Bureau, Mumbai Monday, November 17, 2025, 13:30 Hrs [IST] Alembic ...
Stocks like Max Healthcare Institute, V2 Retail, Narayana Hrudayala, GMR Power and Urban Infra, Ashoka Buildcon, Websol ...
On Monday, Alembic Pharmaceuticals saw a surge in its stock prices after the USFDA greenlit its Diltiazem Hydrochloride ...
Explore the latest updates on Lupin, Alembic Pharma, Maruti Suzuki, and Ola Electric's significant market moves.
Alembic Pharmaceuticals reported a strong second quarter with profit rising 21% year-on-year to ₹185 crore, supported by ...
Vadodara: Pharma firm Alembic Pharmaceuticals Limited has announced that the company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback